Adding the human TLR8 agonist TL8-506 (and thus mimicking RNA activation) to a vaccine with ESAT-6 and alum led to a sustained generation of CD8+ TCM in transgenic mice [20], which could provide a strong Th1 response upon infection with MTB mainly mediated through type I IFNs. Here, CD8A is linked to infection.